Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 22.75 yuan on August 25, 2025, reflecting a 0.35% rise, while the overall market sentiment indicates mixed fund flows [1][2]. Fund Flow Summary - On August 25, 2025, the net outflow of main funds was 435.19 million yuan, accounting for 7.46% of the total transaction amount, while retail investors saw a net inflow of 481.9 million yuan, representing 8.27% of the total [1][2]. - Over the past five days, the fund flow data shows fluctuations, with significant net outflows from main funds on August 22 (2008.72 million yuan) and August 21 (252.93 million yuan), while retail investors had notable inflows on those days [2]. Company Performance Metrics - Chunli Medical's total market value is 8.726 billion yuan, with a net asset value of 2.879 billion yuan and a net profit of 58.071 million yuan, ranking 45th, 52nd, and 42nd respectively in the medical device industry [3]. - The company reported a gross margin of 66.69% and a net margin of 25.25%, both of which are significantly higher than the industry averages of 51.33% and 10.71% respectively [3]. - In the first quarter of 2025, the company's main revenue was 230 million yuan, showing a year-on-year increase of 3.6%, while the net profit increased by 5.2% [3]. Industry Ratings - In the last 90 days, three institutions have issued buy ratings for Chunli Medical, indicating positive sentiment towards the stock [4].

公司公告汇总 春立医疗（证券代码：688236）将于2025年9月1日（星期一）上午10:00-11:00举行2025年半年度业绩说 明会。会议将在上海证券交易所上证路演中心以网络互动形式召开。公司计划在2025年8月30日发布 2025年半年度报告，为让投资者更全面深入地了解公司经营成果和财务状况，将针对2025年半年度的经 营成果及财务指标与投资者进行互动交流。出席人员包括董事长史文玲女士、总经理史春生先生、财务 总监卢宏悦女士和董事会秘书解凤宝先生。投资者可在2025年9月1日上午10:00-11:00通过互联网登录上 证路演中心在线参与，也可在2025年8月25日至8月29日16:00前登录上证路演中心网站首页点击"提问预 征集"栏目或通过公司邮箱ir@clzd.com提问。联系人：公司证券部，电话：010-87321998，邮箱： ir@clzd.com。投资者可通过上证路演中心查看本次投资者说明会的召开情况及主要内容。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年8月22日收盘，春立医疗（688236） ...

Group 1 - The core point of the article highlights the financing activities of Chunli Medical, indicating a net sell-off in recent trading days [1] - On August 22, Chunli Medical had a financing buy-in amount of 0.15 billion, ranking 1288th in the market, with a financing repayment amount of 0.16 billion, resulting in a net sell-off of 0.8917 million [1] - Over the last three trading days (August 20-22), Chunli Medical recorded financing buy-ins of 0.13 billion, 0.07 billion, and 0.15 billion respectively [1] Group 2 - In terms of securities lending, on August 22, there were no shares sold or net sold in the securities lending market for Chunli Medical [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於召開2025年半年度業績說明會的公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年8月22日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 ...

Core Points - The company, Beijing Chunli Zhengda Medical Devices Co., Ltd., will hold a half-year performance briefing on September 1, 2025, from 10:00 to 11:00 AM [1][2] - The briefing will be conducted in an interactive online format via the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions for the briefing from August 25 to August 29, 2025, before 4:00 PM [3] Summary by Sections Meeting Details - The performance briefing is scheduled for September 1, 2025, from 10:00 to 11:00 AM [1][2] - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [1][2] - The meeting will be held in an interactive format, allowing for real-time communication with investors [2] Participation Information - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center on the day of the event [2][3] - Questions can be pre-submitted through the Roadshow Center's website or via the company's email from August 25 to August 29, 2025 [3] Contact Information - The company’s contact for inquiries is the Securities Department, reachable at phone number 010-87321998 or via email at ir@clzd.com [3]

关于召开 2025 年半年度业绩说明会的公告 证券代码：688236 证券简称：春立医疗 公告编号：2025-034 北京市春立正达医疗器械股份有限公司 （一） 会议召开时间：2025 年 9 月 1 日上午 10:00-11:00 （二） 会议召开地点：上证路演中心（https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 25 日（星期一）至 8 月 29 日（星期五）16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提问。公司 将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）将于 2025 年 8 月 30 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经 营成果、财务状况，公司计划于 2025 年 9 月 ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of Spring Medical, which has seen a year-to-date increase of 77.40%, but a decline of 4.84% over the last five trading days [2][3] - As of August 22, Spring Medical's stock price was reported at 22.62 yuan per share, with a market capitalization of 8.676 billion yuan [1] - The company primarily engages in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] Group 2 - Spring Medical's revenue for the first quarter of 2025 reached 230 million yuan, reflecting a year-on-year growth of 3.60%, while the net profit attributable to shareholders was 58.071 million yuan, up 5.20% year-on-year [3] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [4] - As of March 31, 2025, the number of shareholders increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [3]

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a significant net buying in the financing market on August 20, with a net purchase amount of 4.17 million yuan [1] - On August 20, Spring Medical's financing buy amounted to 12.64 million yuan, with a total financing balance of 47.98 million yuan, representing 0.71% of its market capitalization, which is above the 90th percentile of the past year [1] - The company has not engaged in any short selling activities on August 20, with no shares sold or repaid, indicating a stable position in the short selling market [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - As of March 31, Spring Medical reported a revenue of 230 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 3.6%, and a net profit attributable to shareholders of 58.07 million yuan, up 5.2% year-on-year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 3 - As of March 31, 2025, the number of shareholders in Spring Medical increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [2] - Among the top ten circulating shareholders, Zhonggeng Small Cap Value Stock holds 2.87 million shares, remaining unchanged, while Hong Kong Central Clearing Limited increased its holdings by 1.11 million shares to 2.29 million shares [3] - New shareholders include Ping An Low Carbon Economy Mixed A, which holds 1 million shares, while some funds exited the top ten circulating shareholders list [3]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 23.29 yuan on August 20, 2025, reflecting a 1.57% rise, amidst mixed capital flows from different investor categories [1][2]. Group 1: Stock Performance and Capital Flow - On August 20, 2025, Chunli Medical's stock recorded a trading volume of 33,100 hands and a total transaction amount of 76.81 million yuan [1]. - The net inflow of main funds was 2.3652 million yuan, accounting for 3.08% of the total transaction amount, while retail investors experienced a net outflow of 3.998 million yuan, representing 5.20% of the total [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with the highest net inflow of main funds recorded on August 19 at 2.5814 million yuan, and the largest net outflow of retail funds on August 14 at 7.4103 million yuan [2]. Group 2: Financial Metrics and Industry Comparison - Chunli Medical's total market value is 8.933 billion yuan, which is below the industry average of 12.109 billion yuan, ranking 43rd out of 123 companies in the medical device sector [3]. - The company reported a net profit of 58.0711 million yuan for Q1 2025, reflecting a year-on-year increase of 5.2%, with a gross margin of 66.69%, significantly higher than the industry average of 51.29% [3]. - The company's return on equity (ROE) stands at 2.04%, outperforming the industry average of 1.28%, indicating a relatively efficient use of equity capital [3]. Group 3: Analyst Ratings - In the last 90 days, three institutions have provided ratings for Chunli Medical, all of which are buy ratings, indicating a positive outlook from analysts [4].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Spring Medical, which has a current stock price of 23.29 yuan, a PE ratio of 69.87, and a total market capitalization of 8.933 billion yuan [1][2] - The average PE ratio for the medical device industry is 59.32, with a median of 39.97, positioning Spring Medical at the 93rd rank within the industry [1][2] - As of March 31, 2025, Spring Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.071 million yuan, reflecting a year-on-year increase of 5.20%, with a gross margin of 66.69% [1]